Krzysztof Płaciszewski

Krzysztof Płaciszewski


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
KPKrzysztof Płaciszewski
Krzysztof Płaciszewski
WWWaldemar Wierzba
Waldemar Wierzba
JOJanusz Ostrowski
Janusz Ostrowski
Jarosław PinkasJarosław Pinkas
Jarosław Pinkas
Mateusz JankowskiMateusz Jankowski
Mateusz Jankowski
The Internet is one of the most popular information sources. This study aimed to assess the public attitudes towards the use of the Internet for health purposes as well as to identify factors associated with the use of the Internet for health purposes among adults in Poland. A web-based cross-sectional survey was carried out between 9 and 12 September 2022 on a nationwide random-quota sample of 1092 adults in Poland. The study questionnaire included 10 questions on Internet use for health purposes. The most common reason for the use of the Internet for health purposes was searching for information on drugs and their effects (69.9%). Almost two-thirds of participants used the Internet for searching for health information (64.9%), for doctors/medical services (63.4%), or for medical facilities (65.3%). Over half of the participants used the Internet for checking online reviews of doctors (55.2%) and 43.5% of the participants ordered drugs or dietary supplements online. Out of 9 different socioeconomic factors analyzed in this study, having higher education, being female, as well as living in cities from 100,000 to 499,999 residents were the most important factors (p < 0.05) associated with the use of the Internet for health purposes. This study confirmed a high level of adoption of medical Internet in Poland.

16 January 2023 in Annals of Agricultural and Environmental Medicine
Verified
Journal Article
Open access
KPKrzysztof Płaciszewski
Krzysztof Płaciszewski
WWWaldemar Wierzba
Waldemar Wierzba
JOJanusz Ostrowski
Janusz Ostrowski
Jarosław PinkasJarosław Pinkas
Jarosław Pinkas
Mateusz JankowskiMateusz Jankowski
Mateusz Jankowski
Introduction and objective: Poland is an example of a European country that has made significant progress in digitizing healthcare during the last 5 years. There is limited data on the use of eHealth services by different socio-economic groups in Poland during the COVID-19 pandemic The aim of...

10 June 2022 in Medycyna Ogólna i Nauki o Zdrowiu
Verified
Journal Article
Open access
KPKrzysztof Płaciszewski
Krzysztof Płaciszewski
Introduction and objective: The COVID-19 pandemic significantly influenced the development of digitization of the healthcare sector and the implementation of e-Health solutions in Poland. The aim of the study was to analyze e-Health solutions implemented in the healthcare sector in Poland, with...

29 June 2022 in Ginekologia Polska
Verified
Journal Article
Open access
PDF file
WWWaldemar Wierzba
Waldemar Wierzba
Mateusz JankowskiMateusz Jankowski
Mateusz Jankowski
KPKrzysztof Płaciszewski
Krzysztof Płaciszewski
PCPiotr Ciompa
Piotr Ciompa
AJArtur Jakimiuk
Artur Jakimiuk
ADAnna Danska-Bidzinska
Anna Danska-Bidzinska
Objectives: To analyze the incidence and overall survival rate of patients with vulvar cancer in Poland, based on the reporting data from the National Health Fund. Material and methods: The incidence of vulvar cancer in Poland in 2008–2016 (9-year follow-up period) by voivodship and the number of patients undergoing combined hospital treatment were analyzed. For the group of patients treated systemically, overall survival (OS) probability was calculated using the Kaplan-Meier estimation method. Results: In the period 2008–2016 in Poland, the diagnosis of malignant neoplasm of the vulva (C51% group) was made in 29,702 patients. The mean annual prevalence rate per 100,000 inhabitants was 8.3 ± 1.2 for Poland. The largest numbers of patients were reported in Mazowieckie and Slaskie voivodeships and the lowest in Opolskie and Podlaskie voivodeships. The median overall survival of patients treated with the combined method in 2008–2016 in Poland was 64.7 months (95% Cl: 58.0–70.0). One-year survival rate was observed in 77.6% of patients, 2-year in 64.4%, 3-year in 58%, over 5 years — 54.22%. Conclusions: In the years 2008–2016 in Poland, based on the data reported to the National Health Fund, the incidence of vulvar cancer was 4 times higher than the statistics of the National Cancer Registry, the WHO or the USA, which indicates either substantive or reporting errors. In Poland, 54% of patients treated with the combined therapy survive over 5 years which is a much lower result compared to highly developed countries. Objectives: To analyze the incidence and overall survival rate of patients with vulvar cancer in Poland, based on the reporting data from the National Health Fund. Material and methods: The incidence of vulvar cancer in Poland in 2008–2016 (9-year follow-up period) by voivodship and the number of patients undergoing combined hospital treatment were analyzed. For the group of patients treated systemically, overall survival (OS) probability was calculated using the Kaplan-Meier estimation method. Results: In the period 2008–2016 in Poland, the diagnosis of malignant neoplasm of the vulva (C51% group) was made in 29,702 patients. The mean annual prevalence rate per 100,000 inhabitants was 8.3 ± 1.2 for Poland. The largest numbers of patients were reported in Mazowieckie and Slaskie voivodeships and the lowest in Opolskie and Podlaskie voivodeships. The median overall survival of patients treated with the combined method in 2008–2016 in Poland was 64.7 months (95% Cl: 58.0–70.0). One-year survival rate was observed in 77.6% of patients, 2-year in 64.4%, 3-year in 58%, over 5 years — 54.22%. Conclusions: In the years 2008–2016 in Poland, based on the data reported to the National Health Fund, the incidence of vulvar cancer was 4 times higher than the statistics of the National Cancer Registry, the WHO or the USA, which indicates either substantive or reporting errors. In Poland, 54% of patients treated with the combined therapy survive over 5 years which is a much lower result compared to highly developed countries.

9 April 2023 in Journal of Health Policy & Outcomes Research
Verified
Journal Article
Closed access
KPKrzysztof Płaciszewski
Krzysztof Płaciszewski
WWWaldemar Wierzba
Waldemar Wierzba
JOJanusz Ostrowski
Janusz Ostrowski
Jarosław PinkasJarosław Pinkas
Jarosław Pinkas
Mateusz JankowskiMateusz Jankowski
Mateusz Jankowski